Albany, NY -- (SBWIRE) -- 04/01/2014 -- Insulin Delivery Devices Market to 2019 examines the market, competitive landscape, and trends for the four insulin delivery devices market segments: insulin pens, insulin pumps, insulin syringes and traditional insulin pump accessories. It provides comprehensive information on the key trends affecting these segments, and key analytical content on the market dynamics. The report also reviews the competitive landscape, analyzes each segment’s pipeline products and gives details of important mergers and acquisitions. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

View Full Report With Complete TOC at http://www.researchmoz.us/insulin-delivery-devices-market-to-2019-simplified-pump-solutions-and-low-cost-pens-represent-distinct-regional-growth-drivers-report.html

Scope

The markets of 12 key geographies are covered: US, Canada, UK, Germany, France, Italy, Spain, Japan, China, India, Australia and Brazil.
Information on market size for the four insulin delivery devices market segments: insulin pens, insulin pumps, insulin syringes and traditional insulin pump accessories.
Annual market revenue data forecast to 2019 and company share data for 2012.
Qualitative analysis of key trends in the insulin delivery devices market.
Information on the competitive landscape and the leading technologies of key players: Novo Nordisk, Medtronic, Sanofi, Eli Lilly, Becton, Dickinson and Company, Animas, Insulet, F. Hoffmann-La Roche, Abbott Laboratories.
Information on reimbursement trends and market access for key countries.

Browse Other Published Reports By GBI Research at http://www.researchmoz.us/publisher/gbi-research-2.html

Reasons to Buy

Develop business strategies by understanding the trends and developments driving the global insulin delivery devices market.
Design and enhance your product development, marketing, and sales strategies.
Exploit merger and acquisition opportunities by identifying the market players with the most innovative pipelines.
Develop market-entry and market-expansion strategies.
Identify the key players best positioned to take advantage of the emerging market opportunities.
Exploit in-licensing and out-licensing opportunities by identifying the products most likely to ensure a robust return.
Identify, understand and capitalize on the next big thing in the insulin delivery devices market landscape.
Make more informed business decisions from insightful and in-depth analysis of the global insulin delivery devices market and the factors shaping it.

Related Reports -

Glucose Monitoring Device Market to 2019 - Technology Adoption and Increasing Health Awareness Serve as Distinct Regional Growth Drivers

Glucose Monitoring Device Market to 2019 - Technology adoption and increasing health awareness serve as distinct regional growth drivers” looks at the market, competitive landscape, and trends for the three glucose monitoring devices market segments: blood glucose meters, blood glucose testing strips, and lancets. The report provides comprehensive information on the key trends affecting these segments, and key analytical content on the market dynamics. It also reviews the competitive landscape and gives detailed analysis of each segment’s pipeline products, as well as details of important M&A deals. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

View Full Report With Complete TOC at http://www.researchmoz.us/glucose-monitoring-device-market-to-2019-technology-adoption-and-increasing-health-awareness-serve-as-distinct-regional-growth-drivers-report.html

Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation

The Systemic Lupus Erythematosus (SLE) drug market is currently under-served by non-generic, targeted therapies. Whilst the only Food and Drug Administration (FDA)-approved biologic, Benlysta (belimumab), generated sales of $111m in 2012, there is little evidence that the drug’s performance is significantly superior to other B-cell targeted therapies such as Rituxan (rituximab), which is often used off-license to treat refractory SLE patients. Therapeutics entering the market therefore do not face the staggering level of competition from currently marketed programs as in other markets such as the Rheumatoid Arthritis (RA) market. Emerging market entrants that appear to offer significant therapeutic benefits are likely to cause dramatic changes to the market landscape.

View Full Report With Complete TOC at http://www.researchmoz.us/frontier-pharma-systemic-lupus-erythematosus-identifying-and-commercializing-first-in-class-innovation-report.html

About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:
Website@ http://www.researchmoz.us/
Email: sales@researchmoz.us

Browse Blog - http://medicaldevicesoverview.wordpress.com/